In-depth proteomics analysis of sentinel lymph nodes from individuals with endometrial cancer

dc.contributor.authorAboulouard, Soulaimane
dc.contributor.authorWisztorski, Maxence
dc.contributor.authorDuhamel, Marie
dc.contributor.authorSaudemont, Philippe
dc.contributor.authorCardon, Tristan
dc.contributor.authorNarducci, Fabrice
dc.contributor.authorLemaire, Anne Sophie
dc.contributor.authorKobeissy, Firas H.
dc.contributor.authorLeblanc, Éric
dc.contributor.authorFournier, Isabelle
dc.contributor.authorSALZET, Michel
dc.contributor.departmentBiochemistry and Molecular Genetics
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:38:10Z
dc.date.available2025-01-24T11:38:10Z
dc.date.issued2021
dc.description.abstractEndometrial cancer (EC) is one of the most common gynecological cancers worldwide. Sentinel lymph node (SLN) status could be a major prognostic factor in evaluation of EC, but several prospective studies need to be performed. Here we report an in-depth proteomics analysis showing significant variations in the SLN protein landscape in EC. We show that SLNs are correlated to each tumor grade, which strengthens evidence of SLN involvement in EC. A few proteins are overexpressed specifically at each EC tumor grade and in the corresponding SLN. These proteins, which are significantly variable in both locations, should be considered potential markers of overall survival. Five major proteins for EC and SLN (PRSS3, PTX3, ASS1, ALDH2, and ANXA1) were identified in large-scale proteomics and validated by immunohistochemistry. This study improves stratification and diagnosis of individuals with EC as a result of proteomics profiling of SLNs. © 2021 The Authors
dc.identifier.doihttps://doi.org/10.1016/j.xcrm.2021.100318
dc.identifier.eid2-s2.0-85107931637
dc.identifier.pmid34195683
dc.identifier.urihttp://hdl.handle.net/10938/29000
dc.language.isoen
dc.publisherCell Press
dc.relation.ispartofCell Reports Medicine
dc.sourceScopus
dc.subjectAlternative proteins
dc.subjectDiagnosis
dc.subjectEndometrial cancer
dc.subjectGhost proteome
dc.subjectProtein mutations
dc.subjectProteomics
dc.subjectSentinel lymph nodes
dc.subjectAldehyde dehydrogenase, mitochondrial
dc.subjectAmino acid sequence
dc.subjectAnnexin a1
dc.subjectBiomarkers, tumor
dc.subjectC-reactive protein
dc.subjectEndometrial neoplasms
dc.subjectFemale
dc.subjectGene expression profiling
dc.subjectGene expression regulation, neoplastic
dc.subjectHumans
dc.subjectImmunohistochemistry
dc.subjectLymph node excision
dc.subjectLymphatic metastasis
dc.subjectNeoplasm grading
dc.subjectPrognosis
dc.subjectProspective studies
dc.subjectSentinel lymph node
dc.subjectSentinel lymph node biopsy
dc.subjectSerum amyloid p-component
dc.subjectSignal transduction
dc.subjectSurvival analysis
dc.subjectTrypsin
dc.subjectAldehyde dehydrogenase isoenzyme 2
dc.subjectArgininosuccinate synthase
dc.subjectAss1 protein
dc.subjectLipocortin 1
dc.subjectPentraxin 3
dc.subjectPrss3 protein
dc.subjectSerine proteinase
dc.subjectUnclassified drug
dc.subjectAldh2 protein, human
dc.subjectAnxa1 protein, human
dc.subjectC reactive protein
dc.subjectPrss3 protein, human
dc.subjectSerum amyloid p
dc.subjectTumor marker
dc.subjectArticle
dc.subjectCancer grading
dc.subjectControlled study
dc.subjectEndometrium cancer
dc.subjectHuman
dc.subjectHuman tissue
dc.subjectOverall survival
dc.subjectProtein analysis
dc.subjectProtein expression
dc.subjectEndometrium tumor
dc.subjectGene expression regulation
dc.subjectGenetics
dc.subjectLymph node dissection
dc.subjectLymph node metastasis
dc.subjectMetabolism
dc.subjectMortality
dc.subjectPathology
dc.subjectProcedures
dc.subjectProspective study
dc.subjectSurgery
dc.titleIn-depth proteomics analysis of sentinel lymph nodes from individuals with endometrial cancer
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2021-5999.pdf
Size:
7.18 MB
Format:
Adobe Portable Document Format